The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company ... than suggested by their initial clinical staging following transurethral resection of bladder tumor (TURBT).

Using multiparametric MRI (mpMRI) before surgery reduced time to correct ... randomly assigned 1:1 to transurethral resection of bladder tumor (TURBT) or mpMRI-staged care between May 31, 2018 ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap ...

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment ...

covering a variety of urologic issues such as prostate cancer ... the balloon before forced removal. ProArc Medical is a ...

Among these, transurethral resection of bladder tumors (TURBT) has been the standard ... and the quality of pathological specimens obtained during surgery. En bloc resection, which involves ...

Restaging transurethral resection for patients with T1 tumors should ... use of chemotherapeutic agents immediately after surgery or in an adjuvant regimen, use of intravesical immunotherapy ...